EPHA2 and neoplasm: Lin Y.G. et al. recently demonstrated that targeting EphA2 while concomitantly using conventional cytotoxic chemotherapy successfully decreased tumor growth in vivo at least in part by inducing tumor-associated endothelial cell apoptosis [55], supporting EphA2 as a therapeutic antiangiogenic target.